These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 10500044)

  • 1. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.
    Iruela-Arispe ML; Lombardo M; Krutzsch HC; Lawler J; Roberts DD
    Circulation; 1999 Sep; 100(13):1423-31. PubMed ID: 10500044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
    Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
    Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.
    Dawson DW; Volpert OV; Pearce SF; Schneider AJ; Silverstein RL; Henkin J; Bouck NP
    Mol Pharmacol; 1999 Feb; 55(2):332-8. PubMed ID: 9927626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
    Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1.
    Guo NH; Krutzsch HC; Inman JK; Shannon CS; Roberts DD
    J Pept Res; 1997 Sep; 50(3):210-21. PubMed ID: 9309585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1.
    Shafiee A; Penn JS; Krutzsch HC; Inman JK; Roberts DD; Blake DA
    Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2378-88. PubMed ID: 10892887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
    Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
    Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
    Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
    Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity.
    Tolsma SS; Volpert OV; Good DJ; Frazier WA; Polverini PJ; Bouck N
    J Cell Biol; 1993 Jul; 122(2):497-511. PubMed ID: 7686555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins.
    Qabar AN; Bullock J; Matej L; Polverini P
    Biochem J; 2000 Feb; 346 Pt 1(Pt 1):147-53. PubMed ID: 10657251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a).
    Kim JS; Chang JH; Yu HK; Ahn JH; Yum JS; Lee SK; Jung KH; Park DH; Yoon Y; Byun SM; Chung SI
    J Biol Chem; 2003 Aug; 278(31):29000-8. PubMed ID: 12746434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.
    Simantov R; Febbraio M; Crombie R; Asch AS; Nachman RL; Silverstein RL
    J Clin Invest; 2001 Jan; 107(1):45-52. PubMed ID: 11134179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
    Hetian L; Ping A; Shumei S; Xiaoying L; Luowen H; Jian W; Lin M; Meisheng L; Junshan Y; Chengchao S
    J Biol Chem; 2002 Nov; 277(45):43137-42. PubMed ID: 12183450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo.
    Hugo CP; Pichler RP; Schulze-Lohoff E; Pröls F; Adler S; Krutsch HC; Murphy-Ullrich JE; Couser WG; Roberts DD; Johnson RJ
    Kidney Int; 1999 Jun; 55(6):2236-49. PubMed ID: 10354272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta.
    Yee KO; Streit M; Hawighorst T; Detmar M; Lawler J
    Am J Pathol; 2004 Aug; 165(2):541-52. PubMed ID: 15277228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
    Binétruy-Tournaire R; Demangel C; Malavaud B; Vassy R; Rouyre S; Kraemer M; Plouët J; Derbin C; Perret G; Mazié JC
    EMBO J; 2000 Apr; 19(7):1525-33. PubMed ID: 10747021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.